NCT05241613

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

A Phase I Study to Evaluate Safety, Tolerability, PK, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Accutar Biotechnology Inc · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to participants * Evaluate the side effects of AC176 * Evaluate pharmacokinetics of AC176 * Evaluate the effectiveness of AC176

Detailed description

AC176-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC176 given as a single agent. The AC176 is an investigational medicinal product that is a potent orally bioavailable Androgen Receptor (AR) degrader studied for the treatment of Metastatic Castration Resistant Prostate Cancer.

Conditions

• Metastatic Castration Resistant Prostate Cancer

Interventions

Type	Name	Description
DRUG	AC176	AC176 will be given orally (PO) on a 28-day cycle.

Timeline

• Start date: 2022-03-16
• Primary completion: 2024-03-05
• Completion: 2024-03-05
• First posted: 2022-02-16
• Last updated: 2025-02-13

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study